Navigation Links
Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab
Date:8/14/2008

he treatment of patients with cancer. Three additional BiTE antibodies, targeting CD33, CEA and MCSP, respectively, are in preclinical development. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of our product candidates, the development of our BiTE antibody technology, the conduct, timing and results of future clinical trials, expectations of the future expansion of our product pipeline and collaborations, and our plans regarding future presentations of clinical data. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical stu
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Clinical Trials Bootcamp Announces Inaugural Meeting
2. Aon eSolutions Launches Clinical Trials Module
3. Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders
4. NewCardio Announces Positive Results From Third Clinical Validation Study
5. Isis Initiates Clinical Trial of CRP Drug
6. U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)
7. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
8. Journal of the American Dental Association Publishes Key Clinical Data for the Use of OraVerse(TM) a Local Anesthetic Reversal Agent
9. Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma
10. M. D. Anderson to Initiate Clinical Validation Study on Rosetta Genomics MicroRNA-based Diagnostic Assay Identifying the Origin of Cancer Metastases
11. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Medical Corporation (OTC Bulletin Board: CONX), a ... kits, and BG Medicine, Inc. (BGM), a ... a supply agreement whereby Corgenix will manufacture ... assay (ELISA) microtiter format exclusively for BG ... in the United States of the BGM ...
(Date:12/14/2009)... Dec. 14 Southridge LLC ("Southridge"), ... micro-cap companies, is pleased to announce that its affiliated ... up to $15 million in equity financing to Imaging ... the years of financing the growth of Imaging Diagnostic ... continually produce new developments in the field of early ...
(Date:12/14/2009)... Conn., ,Dec. 14 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, ... that it had received a complete response letter ... related to its New Drug Application ("NDA") for ... The letter indicates that the FDA cannot approve ... provides recommendations to address remaining issues. ,, Alan ...
Breaking Medicine Technology:Corgenix and BG Medicine Announce Supply Agreement for BGM Galectin-3(TM) 2Southridge LLC Provides Funding Through Private Equity Agreement with Imaging Diagnostic Systems, Inc. 2Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration 2Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration 3Mindray Medical to Exhibit at MEDICA 2009 in Dusseldorf Germany 60827 1Mindray Medical to Exhibit at MEDICA 2009 in Dusseldorf Germany 60827 2CEL SCI to Conduct First Clinical Study of Investigational LEAPS H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns Hopkins University Sc 60824 1CEL SCI to Conduct First Clinical Study of Investigational LEAPS H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns Hopkins University Sc 60824 2CEL SCI to Conduct First Clinical Study of Investigational LEAPS H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns Hopkins University Sc 60824 3Calbiotech Awarded U S Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 14750 1Calbiotech Awarded U S Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 14750 2
... ARBOR, Mich., July 18 Velcura Therapeutics, Inc.,CEO ... has joined,the Board of Directors of the biotechnology ... a powerful anti-inflammatory,agent stimulating bone formation and inhibiting ... a treatment for rheumatoid arthritis and,other bone diseases., ...
... 17 ,Pieris AG, a bio-pharmaceutical company developing ... therapeutics, and Wacker Biotech GmbH, a,full-service contract ... in the development of Pieris, PRS-050,Anticalin(R) for ... as a next generation VEGF antagonist and,as ...
Other Medicine Technology:Velcura Therapeutics, Inc. Adds William Brinkerhoff to its Board of Directors 2Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology and Will Produce Pieris First Clinical Candidate PRS-050 2
(Date:12/14/2009)... Soft and synthetic red-blood-cell-like particles carry oxygen, drugs, and more… ... ... -- Scientists at UC Santa Barbara, in collaboration with scientists ... mimic the characteristics and key functions of natural red blood ... , , , , ,The primary function of natural ...
(Date:12/14/2009)... The combination of AQUALIPO™ and NaturalFill™ revolutionary new liposuction and ... wrinkling, and plump lips all in one minimally invasive treatment. ... ... -- The combination of AQUALIPO™ and NaturalFill™ can remove excess ... and lips to help people slim down, reduce facial wrinkling ...
(Date:12/14/2009)... Mich., Dec. 14 Pepsi Bottling ... Commonwealth of Kentucky are among the major employers ... fall to help their employees make better decisions ... gives employees a personalized summary of their families, ... that care. With this personalized information, employees can ...
(Date:12/14/2009)... HOLLYWOOD, Fla., Dec. 14 Abbott ... a definitive agreement to acquire STARLIMS Technologies ... provider of laboratory information management systems, for ... The acquisition strengthens Abbott,s competitive position in ... applications to help laboratories efficiently store, retrieve ...
(Date:12/14/2009)... -- Americold Realty Trust ("Americold") announced today that it ... the U.S. Securities and Exchange Commission (the "SEC") relating ... shares. The number of shares to be offered and ... been determined. The common shares to be sold in ... ,, The joint book-running managers of the offering ...
Breaking Medicine News(10 mins):Health News:Synthetic Red Blood Cells Developed 2Health News:Synthetic Red Blood Cells Developed 3Health News: Free Webinar Series at Aqualipo.com Shows How New Combination Liposuction/Fat Transfer Treatment Helps Patients Slim Down and Reduce Facial Wrinkling 2Health News: Free Webinar Series at Aqualipo.com Shows How New Combination Liposuction/Fat Transfer Treatment Helps Patients Slim Down and Reduce Facial Wrinkling 3Health News:Corporations, Universities and State Governments Deploy Thomson Reuters Solution to Improve Employees' Benefit Selection Process 2Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 2Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 3Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 4Health News:Americold Realty Trust Files Registration Statement for Proposed Initial Public Offering 2
... BEVERLY HILLS, Calif., March 6 World-renowned,dermatologist, Dr. ... the public about,the dangers surrounding one of the ... Botox is the second-most recognized,prescription drug brand in ... many,instances, the use of Botox has replaced traditional ...
... Fund Insurance Company,of America recognizes Crissie Insurance Group ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070827/CLM117LOGO ), The ... number of independent,insurance agencies that work with Accident ... volume and profitability goals for the,previous year. Only ...
... rare hereditary disease where the immune system attacks the ... EU project, coordinated by Professor Olle Kmpe at Uppsala ... that opens new possibilities of understanding both APS-1 and ... the American journal The New England Journal of Medicine. ...
... March 6 The Neurologic & Orthopedic Hospital,of Chicago (NOHC) ... spine,surgery according to the Tenth Annual HealthGrades Hospital Quality in,America ... nation,s hospitals over the past three years. The study also,concluded ... in the state of Illinois -- A recipient ...
... LAUREL, N.J., March 6 MedQuist Inc.,(Pink Sheets: ... selected SpeechQ for Radiology(TM) as its front-end interactive ... "most connected healthcare,facilities" by Health Imaging & IT ... largest physician-owned practices in Tucson, with more than ...
... March 6 /PRNewswire-FirstCall/ - Predictive medicine company,PreMD Inc. ... has entered into a,collaboration with one of the ... devices using PreMD,s innovative skin testing,technologies, to enhance ... name of the organization are not being disclosed ...
Other Medicine News:Health News:Founding Father of Modern Cosmetic Dermatology Seeks to Warn Public of Misrepresented Data and Inappropriate Use of Botox 2Health News:Founding Father of Modern Cosmetic Dermatology Seeks to Warn Public of Misrepresented Data and Inappropriate Use of Botox 3Health News:New protein discovery helps researchers understand autoimmune diseases 2Health News:Neurologic & Orthopedic Hospital of Chicago Ranked Among Top in Nation for Spine Surgery 2Health News:Leading Arizona Radiological Group Selects MedQuist for Speech Recognition Solution 2Health News:PreMD Inc. Signs Agreement with Cosmetics Conglomerate 2
TVL defibrillation leads have a patented coiled-coil design for faster, easier insertion and more precise intracardiac placement. Designed with an integrated bipolar design, the lead enables high-vol...
The TVL-ADX lead is a thin, high-performing defibrillation lead that offers a true bipolar configuration designed for smarter sensing and low defibrillation threshold for greater patient safety margi...
... dual-electrode SPL defibrillator lead features ... offering the flexibility and maneuverability ... for the physician who prefers ... coils, the SPL lead also ...
... catheters feature 20 bipolar-spaced electrodes along ... degree of mapping resolution in atrial ... a 20-pole catheter enables more accurate ... with 10-pole catheter systems. The result: ...
Medicine Products: